Bank of America, BofA, reiterates its Buy rating on the pharmaceutical company Genmab and raises its price target to DKK 2,850 from 2,500, according to a recent analysis.
The bank highlights positive phase 3 data for Epkinly in first-line DLBCL, where the hazard ratio for progression-free survival was 0.49.
BofA raises its estimated peak sales for Epkinly to USD 2.5 billion from USD 2 billion. Two further phase 3 results are expected during the fourth quarter and are jointly estimated to represent more than USD 4 billion in potential peak sales.
